Rosuvastatin weight gain
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Rosuvastatin and Weight Gain: Insights from Recent Research
Rosuvastatin's Impact on Weight Gain in Diet-Induced Obesity
High-Fat Diet and Rosuvastatin Treatment in Mice
Research has shown that rosuvastatin can influence weight gain and fat distribution in models of diet-induced obesity. In a study involving male C57Bl/6 mice fed a high-fat diet, rosuvastatin treatment led to a decrease in adiposity and adipocyte size, particularly at doses of 10 mg/kg/day and 20 mg/kg/day. Additionally, at a higher dose of 40 mg/kg/day, rosuvastatin altered fat distribution, promoting subcutaneous rather than visceral fat storage. This redistribution was associated with improvements in fasting glucose levels and glucose intolerance, suggesting that rosuvastatin can mitigate some of the adverse metabolic effects of a high-fat diet.
Rosuvastatin and Weight Gain in Obese Dyslipidaemic Mice
Effects on Blood Pressure and Insulin Sensitivity
In another study focusing on obese dyslipidaemic mice, rosuvastatin was found to normalize blood pressure and its variability without significantly affecting weight gain. The study highlighted that rosuvastatin's benefits in this context were linked to the upregulation of PPARgamma and SOD1 in the endothelium, rather than changes in body weight or plasma cholesterol levels. This suggests that rosuvastatin's effects on metabolic syndrome components may be mediated through mechanisms other than weight reduction.
Comparative Effects of Rosuvastatin, Simvastatin, and Fenofibrate
Weight Gain and Lipid Profiles in Female Rats
A comparative study on female rats treated with oral contraceptives and a high-fat diet examined the effects of simvastatin, rosuvastatin, and fenofibrate on body weight and lipid profiles. While fenofibrate was the most effective in preventing significant weight gain, rosuvastatin also inhibited the rise in triglyceride and total cholesterol levels. However, rosuvastatin did not significantly prevent weight gain in this model, indicating that its primary benefits may lie in lipid profile improvement rather than weight control.
Rosuvastatin and Weight Gain in High Cholesterol Diet Models
Reduction of Gliosis and Weight Gain
In a study involving wild type and ApoE-/- mice on a high cholesterol diet, rosuvastatin treatment resulted in a significant reduction in weight gain, total cholesterol, and low-density lipoprotein levels. The study also found that rosuvastatin reduced gliosis and astrocytic reactivity in the brain, suggesting that its benefits extend beyond lipid-lowering effects to include neuroprotective properties. The correlation between reduced weight gain and decreased gliosis further supports the multifaceted benefits of rosuvastatin in high cholesterol diet models.
Conclusion
Overall, the research indicates that while rosuvastatin may not consistently prevent weight gain across all models, it does offer significant benefits in terms of fat distribution, lipid profile improvement, and metabolic health. Its effects on glucose metabolism, blood pressure regulation, and neuroprotection highlight its potential as a multifaceted therapeutic agent in managing obesity and related metabolic disorders.
Sources and full results
Most relevant research papers on this topic